Fibroscan-aspartate aminotransferase (FAST) score predicts liver-related outcomes, but not extra-hepatic events, in a multicenter cohort of people with HIV
Fibroscan-aspartate aminotransferase (FAST) score predicts liver-related outcomes, but not extra-hepatic events, in a multicenter cohort of people with HIV
"A significant proportion of PWH without viral hepatitis coinfection may have NASH with significant liver fibrosis. FAST score predicts liver-related outcomes and can help risk stratification and management in this high-risk population."
NAFLD if untreated will progresses to NASH, among PLWH the process and progression is faster and the reversal is more gradual and harder due to the virus and antiviral treatment which put this cohort of patients at higher risk compared to general population. Many researchers including Dr. Sebastiani have done quite a bit of work identifying the best ways to improve and validate noninvasive tests for the conditions with the purpose to replace the invasive tests. Liver biopsy will make it harder to screen patients, enrol them in clinical trials and identifying them for treatment once a drug is approved for the disease.
Again THTX's NASH trials was performed on only "high risk" HIV patients which other trials have been avoiding due to the harder to treat HIV liver.